| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alison L McCormack, Sally K Mak, Jaimie M Henderson, David Bumcrot, Matthew J Farrer, Donato A Di Mont. Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PloS one. vol 5. issue 8. 2010-11-04. PMID:20711464. |
in particular, it did not cause tissue inflammation and did not change (i) the number and phenotype of nigral dopaminergic neurons, and (ii) the concentrations of striatal dopamine and its metabolites. |
2010-11-04 |
2023-08-12 |
monkey |
| Joanne Clark, Elizabeth L Clore, Kangni Zheng, Anthony Adame, Eliezer Masliah, David K Simo. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PloS one. vol 5. issue 8. 2010-11-04. PMID:20808797. |
despite the transient nature of the impact of nac on brain glutathione, the loss of dopaminergic terminals at 1 year associated with snca overexpression was significantly attenuated by nac supplementation, as measured by immunoreactivity for tyrosine hydroxylase in the striatum (p = 0.007; unpaired, two-tailed t-test), with a similar but nonsignificant trend for dopamine transporter (dat) immunoreactivity. |
2010-11-04 |
2023-08-12 |
mouse |
| Xiaowei Zhang, Elaine L Bearer, Benoit Boulat, F Scott Hall, George R Uhl, Russell E Jacob. Altered neurocircuitry in the dopamine transporter knockout mouse brain. PloS one. vol 5. issue 7. 2010-10-28. PMID:20634895. |
in the present work we use the unique properties of magnetic resonance imaging (mri) to probe the effects of altered dopaminergic dynamics on meso-scale neuronal circuitry and overall brain morphology, since changes at these levels of organization might help to account for some of the extensive pharmacological and behavioral differences observed in dopamine transporter (dat) ko mice. |
2010-10-28 |
2023-08-12 |
mouse |
| Toshihiko Aosaki, Masami Miura, Takeo Suzuki, Kinya Nishimura, Masao Masud. Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatrics & gerontology international. vol 10 Suppl 1. 2010-10-21. PMID:20590830. |
the timing of the pause phase coincides well with the surge in dopaminergic firing, indicating that a dramatic rise in dopamine (da) release occurs while nicotinic receptors remain unbound by acetylcholine. |
2010-10-21 |
2023-08-12 |
Not clear |
| Gregory C Hadlock, Pei-Wen Chu, Elliot T Walters, Glen R Hanson, Annette E Fleckenstei. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation. The Journal of pharmacology and experimental therapeutics. vol 335. issue 1. 2010-10-21. PMID:20622144. |
methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of d2 receptor activation. |
2010-10-21 |
2023-08-12 |
Not clear |
| Qing Zhao, Junpeng Gao, Wenwei Li, Dingfang Ca. Neurotrophic and neurorescue effects of Echinacoside in the subacute MPTP mouse model of Parkinson's disease. Brain research. vol 1346. 2010-10-19. PMID:20478277. |
we found that oral administration of ech (30 mg/kg/day for 14 days) to mptp-treated mice, commencing after impairment of the nigrstriatal system, suppressed the reduction of nigral dopaminergic neurons, striatal fibers, dopamine and dopamine transporter to 134.24%, 203.17%, 147.25% and 154.72 of mptp-lesioned animals respectively (p<0.05). |
2010-10-19 |
2023-08-12 |
mouse |
| Jens Leander Johansen, Thomas Nikolaj Sager, Julie Lotharius, Louise Witten, Arne Mørk, Jan Egebjerg, Kenneth Thirstru. HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells. Journal of neurochemistry. vol 115. issue 1. 2010-10-13. PMID:20649842. |
hif prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells. |
2010-10-13 |
2023-08-12 |
rat |
| Jens Leander Johansen, Thomas Nikolaj Sager, Julie Lotharius, Louise Witten, Arne Mørk, Jan Egebjerg, Kenneth Thirstru. HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells. Journal of neurochemistry. vol 115. issue 1. 2010-10-13. PMID:20649842. |
we therefore sought out to characterize the effect of hif-up-regulation on survival and dopamine homeostasis in dopaminergic cells. |
2010-10-13 |
2023-08-12 |
rat |
| C A Jones, L C Johnston, M J Jackson, L A Smith, G van Scharrenburg, S Rose, P G Jenner, A C McCrear. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 20. issue 8. 2010-10-12. PMID:20434890. |
partial d(2/3) dopamine (da) receptor agonists provide a novel approach to the treatment of the motor symptoms of parkinson's disease (pd) that may avoid common dopaminergic side-effects, including dyskinesia and psychosis. |
2010-10-12 |
2023-08-12 |
rat |
| Adarsh M Kumar, J B Fernandez, Elyse J Singer, Deborah Commins, Drenna Waldrop-Valverde, Raymond L Ownby, Mahendra Kuma. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. Journal of neurovirology. vol 15. issue 3. 2010-10-06. PMID:19499455. |
in this study, we investigated the impact of hiv-1 on dopaminergic activity with respect to concentrations of dopamine (da) and homovanillic acid (hva) in different regions of postmortem human brains of hiv-1-negative and hiv-1+ individuals and their relationship to neurocognitive impairment. |
2010-10-06 |
2023-08-12 |
human |
| Chun-Jung Lin, Ying Tai, Miao-Tzu Huang, Yuan-Feen Tsai, Hao-Jui Hsu, Kai-Yuan Tzen, Horng-Huei Lio. Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. Journal of neurochemistry. vol 114. issue 3. 2010-10-06. PMID:20477935. |
mptp-induced dopaminergic toxicity was examined by measuring dopamine levels in the brain striatum and by positron emission tomography scanning. |
2010-10-06 |
2023-08-12 |
mouse |
| Chun-Jung Lin, Ying Tai, Miao-Tzu Huang, Yuan-Feen Tsai, Hao-Jui Hsu, Kai-Yuan Tzen, Horng-Huei Lio. Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. Journal of neurochemistry. vol 114. issue 3. 2010-10-06. PMID:20477935. |
mptp-induced dopaminergic toxicity in mice was ameliorated by amantadine without stimulating dopamine turnover. |
2010-10-06 |
2023-08-12 |
mouse |
| Jie Yuan, Martin Darvas, Bethany Sotak, George Hatzidimitriou, Una D McCann, Richard D Palmiter, George A Ricaurt. Dopamine is not essential for the development of methamphetamine-induced neurotoxicity. Journal of neurochemistry. vol 114. issue 4. 2010-10-06. PMID:20533999. |
it is widely believed that dopamine (da) mediates methamphetamine (meth)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with da neurotransmission decrease toxicity, whereas drugs that increase da neurotransmission enhance toxicity. |
2010-10-06 |
2023-08-12 |
mouse |
| Adrian Newman-Tancred. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Current opinion in investigational drugs (London, England : 2000). vol 11. issue 7. 2010-10-05. PMID:20571976. |
indeed, extensive evidence in rodent models indicates that the activation of these receptors prevents extrapyramidal symptoms (eps) induced by dopamine d2 receptor blockade, favors dopaminergic neurotransmission in the frontal cortex, has a positive influence on mood, and opposes nmda receptor antagonist-induced cognitive and social interaction deficits. |
2010-10-05 |
2023-08-12 |
Not clear |
| Ali Jahanshahi, Rinske Vlamings, Ahmet Hilmi Kaya, Lee Wei Lim, Marcus L F Janssen, Sonny Tan, Veerle Visser-Vandewalle, Harry W M Steinbusch, Yasin Teme. Hyperdopaminergic status in experimental Huntington disease. Journal of neuropathology and experimental neurology. vol 69. issue 9. 2010-10-05. PMID:20720506. |
huntington disease has been linked to increased dopaminergic neurotransmission in the striatum, and clinical studies have demonstrated that the associated chorea can be treated with dopamine antagonist or dopamine-depleting drugs. |
2010-10-05 |
2023-08-12 |
rat |
| Ali Jahanshahi, Rinske Vlamings, Ahmet Hilmi Kaya, Lee Wei Lim, Marcus L F Janssen, Sonny Tan, Veerle Visser-Vandewalle, Harry W M Steinbusch, Yasin Teme. Hyperdopaminergic status in experimental Huntington disease. Journal of neuropathology and experimental neurology. vol 69. issue 9. 2010-10-05. PMID:20720506. |
because substantia nigra pars compacta and the ventral tegmental area are the main sources of striatal dopamine input, we hypothesized that changes in these regions relate to striatal dopaminergic alterations. |
2010-10-05 |
2023-08-12 |
rat |
| Takaaki Matsuo, Yasuhiko Izumi, Seiko Wakita, Toshiaki Kume, Yuki Takada-Takatori, Hideyuki Sawada, Akinori Akaik. Haloperidol, spiperone, pimozide and aripiprazole reduce intracellular dopamine content in PC12 cells and rat mesencephalic cultures: Implication of inhibition of vesicular transport. European journal of pharmacology. vol 640. issue 1-3. 2010-10-04. PMID:20460122. |
accumulating evidence suggests that antipsychotics affect dopamine release from dopaminergic neurons, but the precise mechanisms are not fully understood. |
2010-10-04 |
2023-08-12 |
rat |
| Robert A Hodgson, Paul J Bedard, Geoffrey B Varty, Tatiana M Kazdoba, Therese Di Paolo, Michael E Grzelak, Annamarie J Pond, Abdallah Hadjtahar, Nancy Belanger, Laurent Gregoire, Aurelie Dare, Bernard R Neustadt, Andrew W Stamford, John C Hunte. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Experimental neurology. vol 225. issue 2. 2010-10-01. PMID:20655910. |
parkinson's disease (pd) and extrapyramidal syndrome (eps) are movement disorders that result from degeneration of the dopaminergic input to the striatum and chronic inhibition of striatal dopamine d(2) receptors by antipsychotics, respectively. |
2010-10-01 |
2023-08-12 |
monkey |
| Cynthia Kuhn, Misha Johnson, Alex Thomae, Brooke Luo, Sidney A Simon, Guiying Zhou, Q David Walke. The emergence of gonadal hormone influences on dopaminergic function during puberty. Hormones and behavior. vol 58. issue 1. 2010-09-30. PMID:19900453. |
the purpose of this review is to summarize the contribution of sex differences in the function of ascending dopamine systems that are critical to reinforcement, to briefly summarize the behavioral, neurochemical and anatomical changes in brain dopaminergic functions related to addiction that occur during adolescence and to present new findings about the emergence of sex differences in dopaminergic function during adolescence. |
2010-09-30 |
2023-08-12 |
Not clear |
| G Biju, R de la Fuente-Fernánde. Dopaminergic function and progression of Parkinson's disease: PET findings. Parkinsonism & related disorders. vol 15 Suppl 4. 2010-09-30. PMID:20123555. |
the progressive loss of dopaminergic neurons is accompanied by several functional adaptive changes in surviving nerve terminals, which lead to increased dopamine turnover and raise the risk of treatment-related motor complications. |
2010-09-30 |
2023-08-12 |
Not clear |